Kite Pharma (KITE) : Tuesdays money flow points at investors jumping to buy the stock on the weakness of price. $14.17 million worth of transactions were on upticks, whereas, the downticks accounted for $10.82 million worth of transactions. The net money flow was a positive $3.35 million and the uptick to downtick ratio was 1.31. The net money flow into the stock was $2.24 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $2.24 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Kite Pharma (KITE) was trading at $46.96, down $0.72 during day. The stock slid -1.51% over the previous days close. For the week, the stock recorded -3.24% over the previous weeks close.
The company Insiders own 20.6% of Kite Pharma shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -7.09% . Institutional Investors own 74.78% of Kite Pharma shares. During last six month period, the net percent change held by insiders has seen a change of -7.09%. In an insider trading activity,The officer (SVP Clinical Development) of Kite Pharma, Inc., Wiezorek Jeffrey sold 1,500 shares at $50.01 on July 1, 2016. The Insider selling transaction had a total value worth of $75,015. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Kite Pharma, Inc. has lost 8.67% in the last five trading days and dropped 8.46% in the last 4 weeks. Kite Pharma, Inc. has dropped 7.32% during the last 3-month period . Year-to-Date the stock performance stands at -23.79%.
Kite Pharma (NASDAQ:KITE): On Tuesdays trading session , Opening price of the stock was $48.04 with an intraday high of $48.38. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $46.89. However, the stock managed to close at $46.96, a loss of 1.51% for the day. On the previous day, the stock had closed at $47.68. The total traded volume of the day was 1,416,380 shares.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Companys lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.